[1] Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol, 2010; 299, F14-25. doi:  10.1152/ajprenal.00200.2010
[2] Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol, 2008; 10, 25-36. http://www.chd.ucsd.edu/_files/winter2009/Liu.GeneEnvInteraction.HumanDisease.08.pdf
[3] Kikuyama M, Takeshima H, Kinoshita T, et al. Development of a novel approach, the epigenome-based outlier approach, toidentify tumor-suppressor genes silenced by aberrant DNA methylation. Cancer Lett, 2012; 322, 204-12. doi:  10.1016/j.canlet.2012.03.016
[4] Villeneuve LM, Reddy MA, Natarajan R. Epigenetics:deciphering its role in diabetes and its chronic complications. Clin Exp Pharmacol Physiol, 2011; 38, 451-9. doi:  10.1111/j.1440-1681.2011.05497.x
[5] Xiao X, Zhang ZX, Cohen HJ, et al. Evidence of a relationship between infant birth weight and later diabetes and impaired glucose regulation in a Chinese population. Diabetes Care, 2008;31, 483-7. doi:  10.2337/dc07-1130
[6] Xiao X, Zhang ZX, Li WH, et al. Low birth weight is associated with components of the metabolic syndrome. Metabolism, 2010; 59, 1282-6. doi:  10.1016/j.metabol.2009.12.001
[7] Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med, 2002; 8, 1288e95. http://www.sigmaaldrich.com/catalog/papers/12368907
[8] Collins QF, Xiong Y, Lupo EG Jr, et al. p38 Mitogen-activated protein kinase mediates free fatty acid-inducedgluconeogenesis in hepatocytes. J Biol Chem, 2006; 281, 24336-44. doi:  10.1074/jbc.M602177200
[9] Wu JJ, Roth RJ, Anderson EJ, et al. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity andresistance to diet-induced obesity. Cell Metab, 2006; 4, 61-73. doi:  10.1016/j.cmet.2006.05.010
[10] Feng B, Ruiz MA, Chakrabarti S. Oxidative-stress-induced epigenetic changes in chronic diabetic complications. Can J Physiol Pharmacol, 2013; 91, 213-20. doi:  10.1139/cjpp-2012-0251